Predicting early chemotherapy response with technetium-99m methoxyisobutylisonitrile SPECT/CT in advanced non-small cell lung cancer

Molecular Imaging and Biology

Volumn 12, Issue 2, 2010, Pages 174-180

  Yang, Tzu I J ^a,b   Aukema, Tjeerd S ^a   Van Tinteren, Harm ^a   Burgers, Sjaak ^a   Olmos, Renato Valdés ^a   Verheij, Marcel ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

99mTc MIBI; Non small cell lung cancer; Prognostic indicator; RECIST; SPECT CT; Treatment response

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77953510243     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0250-z     Document Type: Article

References (33)

1. Chiu ML, Kronauge JF, Piwnica-Worms D (1990) Effect of mitochon-drial and plasma membrane potentials on accumulation of hexakis (2- methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 31:1646-1653
2. Wackers FJ, Berman DS, Maddahi J et al (1989) Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 30:301-311
3. Bom HS, Kim YC, Song HC et al (1998) Technetium-99m-MIBI uptake in small cell lung cancer. J Nucl Med 39:91-94
4. Ceriani L, Giovanella L, Bandera M et al (1997) Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy. Nucl Med Commun 18:1087-1097
5. Kao CH, ChangLai SP, Chieng PU et al (1998) Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma: relation to patient prognosis and chemotherapy response - a preliminary report. Cancer 83:64-68
6. Kao CH, Hsieh JF, Tsai SC et al (2000) Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography. Clin Cancer Res 6:820-824
7. Nishiyama Y, Yamamoto Y, Satoh K et al (2000) Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. Clin Nucl Med 25:364-369
8. Yamamoto Y, Nishiyama Y, Satoh K et al (2000) Comparative evaluation of Tc-99m MIBI and Tl-201 chloride SPECT in non-small-cell lung cancer mediastinal lymph node metastases. Clin Nucl Med 25:29-32
9. Moretti JL, Azaloux H, Boisseron D et al (1996) Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression. Eur J Nucl Med 23:980-986
10. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H et al (1995) Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 22:434-442
11. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med 44:1394-1401
12. Bellamy WT (1996) P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 36:161-183
13. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427
14. Muzzammil T, Moore MJ, Hedley D et al (2001) Comparison of (99m) Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function. Br J Cancer 84:367-373
15. Germann UA (1996) P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A:927-944
16. Muzzammil T, Ballinger JR, Moore MJ (1999) 99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer. Nucl Med Commun 20:115-122
17. Del Vecchio S, Ciarmiello A, Salvatore M (1999) Clinical imaging of multidrug resistance in cancer. Q J Nucl Med 43:125-131
18. 99mTc-MIBI in the evaluation of breast cancer biology. Eur J Nucl Med Mol Imaging 31(Suppl 1):S88-S96
19. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
20. Kao A, Shiun SC, Hsu NY et al (2001) Technetium-99m methoxyiso- butylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression. Ann Oncol 12:1561-1566
21. Akgun A, Cok G, Karapolat I et al (2006) Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer. Ann Nucl Med 20:269-275
22. 99mTc- HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl Med Commun 29:39-44
23. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310
24. Del Vecchio S, Ciarmiello A, Salvatore M (2000) Scintigraphic detection of multidrug resistance in cancer. Cancer Biother Radiopharm 15:327-337
25. Piwnica-Worms D, Kronauge JF, Chiu ML (1990) Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 82:1826-1838
26. Reed JC (2001) Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med 7:314-319
27. 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. Eur J Nucl Med Mol Imaging 30:879-887
28. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis. Eur J Nucl Med Mol Imaging 29:876-881
29. Shih CM, Hsu WH, Huang WT et al (2003) Usefulness of chest single photon emission computed tomography with technetium-99m methox-yisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer. Cancer Lett 199:99-105
30. 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol 25:2534-2539
31. 99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 35:509-518
32. Kostakoglu L, Kiratli P, Ruacan S et al (1998) Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 39:228-234
33. 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients. Eur J Nucl Med Mol Imaging 29:809-814